OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.

Separately, Evercore ISI dropped their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.38.

OraSure Technologies Stock Down 0.5 %

OraSure Technologies stock opened at $5.50 on Tuesday. OraSure Technologies has a 12-month low of $4.38 and a 12-month high of $8.45. The business’s 50-day moving average price is $6.39 and its two-hundred day moving average price is $6.81. The stock has a market cap of $420.81 million, a PE ratio of 7.64 and a beta of 0.15.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The business had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. During the same period in the prior year, the firm posted $0.21 EPS. OraSure Technologies’s quarterly revenue was down 38.3% compared to the same quarter last year. As a group, analysts expect that OraSure Technologies will post -0.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Trexquant Investment LP raised its stake in shares of OraSure Technologies by 3.3% in the 3rd quarter. Trexquant Investment LP now owns 64,644 shares of the medical instruments supplier’s stock valued at $383,000 after acquiring an additional 2,049 shares in the last quarter. Diversified Trust Co raised its stake in shares of OraSure Technologies by 17.7% in the 4th quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 2,406 shares in the last quarter. AJOVista LLC bought a new position in OraSure Technologies in the 4th quarter worth approximately $39,000. Deutsche Bank AG increased its position in OraSure Technologies by 3.1% in the 3rd quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock worth $1,165,000 after buying an additional 5,875 shares during the period. Finally, Los Angeles Capital Management LLC increased its position in OraSure Technologies by 2.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 341,125 shares of the medical instruments supplier’s stock worth $2,098,000 after buying an additional 8,523 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.